A look at aftermarket performance for 2021’s NASDAQ IPO class: Data Byte

With a postponement, a withdrawal and weakening aftermarket performance of NASDAQ IPOs, signs have begun to appear that investors’ long-robust appetite for new biotech listings has begun to wane.

While stem cell transplantation company Talaris Therapeutics Inc. (NASDAQ:TALS) was able to price at the midpoint of its proposed range late Thursday to raise $150 million, its tepid aftermarket performance was all too familiar. Talaris spent most of the day below its $17 offering price, and closed at $16.25...